MARLBOROUGH, Mass.,, Feb. 25, 2026 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (NASDAQ: IPGP), the global leader in fiber laser technology, announced today that the Local Division of the Unified Patent Court (UPC) located in Mannheim, Germany has issued a decision in a patent infringement case brought by Trumpf SE & Co. KG (“Trumpf”). The court ruled that certain designs of IPG’s adjustable mode beam (AMB) lasers used in welding and cutting applications infringed European Patent 2,951,625. The decision im ...

Core Viewpoint - Novo Nordisk has initiated a U.S. patent lawsuit against Hims & Hers, targeting the sale of compounded versions of its weight-loss drug Wegovy, marking a significant escalation in its legal strategy against compounding pharmacies [1][2]. Legal Context - This lawsuit is Novo's first against a compounding pharmacy in the U.S. regarding Wegovy, coinciding with the FDA's announcement that the active ingredient semaglutide is no longer in short supply, which has lessened concerns about public backlash from patent enforcement [2][3]. - Hims & Hers recently launched a $49 compounded version of Wegovy but quickly retreated after the FDA indicated it would take action against the company [3]. Financial Implications - Hims & Hers has projected its total revenue to exceed $2.3 billion by 2025 and aims for $6.5 billion by 2030, indicating rapid growth in the telehealth sector [4]. Regulatory Environment - U.S. regulations permit compounding pharmacies to produce and sell brand-name medicines if they are in short supply, but without a shortage, compounding is generally allowed only for customized patient needs [5]. - The FDA had previously listed semaglutide as in short supply in 2022, which facilitated the rise of compounding, but declared the shortage over in February 2025 [6]. Previous Legal Actions - Novo Nordisk has previously filed lawsuits against smaller compounding pharmacies for selling unsafe or falsely advertised Wegovy "knockoffs," focusing on safety and trademark rights during the semaglutide shortage [7].

Let's begin with Novo Nordisk suing hims and hers, accusing the telehealth firm of infringing its U.S. patent on key ingredient in its epic. And we go by. Let's get the latest.The same for he's the senior pharmaceutical analyst at Bloomberg Intelligence. Sam, we were just talking on Friday and you were telling us there is a danger to this. This isn't good.It sounds like hims and hers has finally listened to some of the criticism and threats coming from regulators. Yeah, well, Daddy, the point here is not ab ...

Core Viewpoint - Ubiquiti (UI) is facing legal challenges from Ax Wireless, LLC regarding alleged patent infringements related to Wi-Fi 6 technology, which could significantly impact its business operations and financial condition [1] Group 1: Legal Proceedings - On February 2, 2026, Ax Wireless filed a complaint against Ubiquiti with the U.S. International Trade Commission (ITC) alleging infringement of several U.S. patents related to Wi-Fi 6 technology [1] - The patents in question include U.S. Patent Nos. 10,079,707; 10,917,272; 11,646,927; 11,777,776; and 11,812,134 [1] - Ax Wireless is seeking a limited exclusion order and a cease and desist order to prevent Ubiquiti from importing and selling certain wireless networking products in the U.S. [1] Group 2: Financial Implications - Concurrently, Ax Wireless has filed a related complaint in the U.S. District Court for the Northern District of Illinois, seeking unspecified monetary damages, interest, and fees [1] - Ubiquiti plans to vigorously defend itself in both the ITC investigation and the District Court action, but there is no assurance of a favorable outcome [1] - An adverse ruling at the ITC could lead to exclusion of Ubiquiti's products from the U.S. market, potentially resulting in a material adverse effect on the company's business, financial condition, and results of operations [1]

Core Viewpoint - Bayer and its Monsanto division are suing COVID-19 vaccine manufacturers, claiming they used patented technology developed by Monsanto in the 1980s without permission [1][3]. Group 1: Lawsuits and Allegations - Bayer alleges that Pfizer, BioNTech, and Moderna improperly utilized technology that Monsanto developed to make plants resistant to insects, which was incorporated into their vaccines to enhance mRNA stability and immunity [3]. - The lawsuits were filed on January 6 in a U.S. court in Delaware, seeking damages for patent infringement [3]. - Bayer is not seeking to halt vaccine production but is requesting monetary compensation for the alleged infringement, stating that the defendants have profited significantly from vaccine sales [4]. Group 2: Financial Impact - Pfizer reported earnings of $11.2 billion in 2023 from its COVID-19 vaccine, highlighting the substantial financial gains made by vaccine manufacturers during the pandemic [5]. - BioNTech acknowledged the lawsuit but declined to comment further, while Moderna stated it would defend against the claims [5][6]. Group 3: Additional Legal Actions - Bayer has also filed a separate lawsuit against Johnson & Johnson, claiming infringement related to its COVID-19 vaccine, which utilized DNA delivery rather than mRNA [6]. - The complaint against Johnson & Johnson asserts that its vaccine's effectiveness relied on the patented technology developed by Bayer [7]. - A previous ruling in England found that Pfizer infringed on a Moderna patent, indicating ongoing legal disputes within the vaccine industry [8].

Core Viewpoint - The United States International Trade Commission (ITC) has initiated an investigation into Samsung and its customers, Google and Super Micro, based on a complaint from Netlist regarding patent infringement [1] Group 1: Investigation Details - The ITC's investigation is a response to a complaint filed by Netlist on September 30, 2025 [1] - The investigation will assess whether Samsung's memory products should be banned from importation into the United States [1] - The complaint involves allegations of infringement on six patents held by Netlist [1]

Core Viewpoint - Life360 is actively challenging a patent infringement claim by GoCodes, asserting that the patent in question is invalid and lacks merit [1][2]. Group 1: Legal Actions - Life360 has filed a complaint in the District of Delaware seeking a declaratory judgment to invalidate GoCodes, Inc.'s U.S. Patent No. 8,973,813, which GoCodes previously claimed Life360 infringed [1]. - GoCodes voluntarily dismissed its patent infringement lawsuit against Life360 on July 23, 2025, without prejudice [1]. Group 2: Patent Validity Arguments - The complaint argues that GoCodes' patent is a patent-ineligible, abstract, and generic idea, supported by extensive publicly available prior art that predates the patent [2]. Group 3: Company Background and Achievements - Life360 has a history of defending its innovations against meritless litigation, having previously won a case against AGIS Inc. in 2015, which was deemed "exceptionally weak" [3]. - Tile, a subsidiary of Life360, successfully invalidated the majority of claims in a patent-infringement suit by Cellwitch, leading to a summary judgment confirming no infringement [3]. - Life360 serves approximately 91.6 million monthly active users across more than 180 countries, providing services that enhance family safety and connection [4].

Core Points - Netlist, Inc. has announced a joint public interest comment filed by the United States Patent and Trademark Office (USPTO) and the United States Department of Justice (USDOJ) regarding its complaint against Samsung, Google, and Super Micro [1] - The company is seeking exclusion and cease and desist orders to prevent Samsung's memory products that infringe its patents from entering the U.S. [1] - Netlist claims that the Respondents infringe on its U.S. Patent Nos. [1]

Core Insights - Two major Indian IT services companies, Tata Consultancy Services (TCS) and Wipro, are facing patent infringement lawsuits, indicating challenges in their service expansion efforts [1][6] - The Indian IT sector, valued at $283 billion, is already experiencing low demand for IT services, and the rise in patent disputes adds to the difficulties [1][6] Group 1: Patent Infringement Cases - Calibrate Networks LLC filed a lawsuit against TCS for allegedly using and selling technology that infringes on its patent related to software application naming [2][3] - The lawsuit claims TCS knowingly continued to use the patented technology even after being served with the complaint [4][6] - Wipro is facing a similar lawsuit from Mobility Workx LLC, which accuses it of infringing on three patents related to wireless testing and 5G services [8][9] Group 2: Legal and Financial Implications - Both TCS and Wipro are experiencing revenue declines, with TCS facing its first-ever revenue drop and Wipro undergoing a turnaround after two years of decline [23] - The ongoing legal battles may affect client confidence in scaling AI and cloud programs, as legal issues surrounding intellectual property can raise concerns during deal cycles [24] - TCS has recently been fined $194 million for trade secret theft, adding to the financial pressures faced by the company [6][21] Group 3: Industry Trends - The shift from traditional IT services to software and platform-based models has increased the risk of intellectual property violations for Indian IT firms [19][20] - Experts suggest that the frequency of patent disputes indicates that global patent holders are closely monitoring the Indian IT sector as it operates in higher value, higher IP zones [20]

Core Viewpoint - A federal jury in California has ruled that Apple must pay Masimo $634 million for infringing on a patent related to blood-oxygen reading technology [1] Company Summary - Apple is facing a significant financial liability due to the jury's decision, which could impact its financial performance and market perception [1] - Masimo, a medical-monitoring technology company, has successfully defended its patent rights, potentially enhancing its market position and credibility in the healthcare technology sector [1]